Grufity logoGrufity logo

EDIT

9.87USD-0.16(-1.60%)Market Closed

Editas Medicine Inc

Market Summary

USD9.87-0.16Market Closed
-1.60%

EDIT Stock Price

RSI Chart

Valuation

Market Cap

875.7M

Price/Earnings

-4.75

Price/Sales

27.54

Price/Cashflow

-5.39

Price/Sales

Profitability

Return on Equity

-39.64%

Return on Assets

-31.76%

Fundamentals

Revenue

Revenue Y/Y

0.22%

Revenue Q/Q

-6.04%

Earnings

Earnings (TTM)

-201.1M

Earnings Y/Y

-42.59%

Earnings Q/Q

-4.25%

Price Action

52 Week Range

9.5933.86
(Low)(High)

Last 7 days

-4.0%

Last 30 days

-22.5%

Last 90 days

-34.7%

Trailing 12 Months

-69.5%

Financial Health

Current Ratio

12.67

Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-2.92

Peers (Alternatives to Editas Medicine)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
3.93% 44.98%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
7.49% 27.03%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
16.17% -46.79%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
2.68% 20.17%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
5.27% 39.87%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
-2.67% -35.96%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-11.41% -45.13%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-11.65% -63.33%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
3.17% -38.24%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.72% -92.37%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-26.30% -79.52%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
7.36% -33.10%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-21.49% -58.93%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-29.05% -90.98%
-13.56
44.06
522.71% -129.91%
218.9M
-
-28.90% -83.56%
-2.36
609.63
-71.03% -64.56%

Financials for Editas Medicine

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-100.0%null32292648
Operating Expenses5.6%230218213219242
  S&GA Expenses0.1%6969747675
  R&D Expenses8.1%161148139143166
Net Income-9.0%-201.13-184.49-186.29-192.50-213.56
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.6%531581623677717
  Current Assets-7.5%427461497507568
    Cash Equivalents24.4%211169211204260
  Net PPE-4.3%1516171716
Liabilities0.7%116115110124130
  Current Liabilities16.1%4236374751
Shareholder's Equity-10.9%415465513554587
  Retained Earnings-5.8%-1,017.39-961.67-908.21-857.70-816.30
  Additional Paid-In Capital0.4%1,4361,4301,4231,4121,403
Shares Outstanding0.1%6969696868
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-4.4%-169.66-162.44-163.55-163.80-169.32
  Share Based Compensation-11.6%3236434341
Cashflow From Investing1272.1%119-10.13-1.34-54.47-140.52
Cashflow From Financing-58.4%2421282290

Risks

What is the probability of a big loss on EDIT?

100%


Probability that Editas Medicine stock will be more than 20% underwater in next one year

88.8%


Probability that Editas Medicine stock will be more than 30% underwater in next one year.

76.2%


Probability that Editas Medicine stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EDIT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Editas Medicine was unfortunately bought at previous high price.

Returns

Cumulative Returns on EDIT

-18.8%


5-Year Cumulative Returns

-31.2%


3-Year Cumulative Returns

What are the long-term rolling returns for EDIT?

FIve years rolling returns for Editas Medicine.

Which funds bought or sold EDIT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
B. Riley Wealth Advisors, Inc.
NEW
-
132,000
132,000
-%
2022-11-22
IHT Wealth Management, LLC
NEW
-
165,000
165,000
0.01%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
698,000
698,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
20,000
1,057,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
10.71
152,000
1,191,000
-%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
-
4,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-19,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
5,000
143,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
UNCHANGED
-
-
8,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
5,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying EDIT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own EDIT

Editas Medicine News

Yahoo Finance

Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain | DelveInsight.18 hours ago

EDIT Fair Value

Recent SEC filings of Editas Medicine

View All Filings
Date Filed Form Type Document
Nov 17, 2022
8-K
Current Report
Nov 09, 2022
4
Insider Trading
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Oct 07, 2022
SC 13G/A
Major Ownership Report
Sep 08, 2022
4
Insider Trading
Sep 08, 2022
4
Insider Trading

Latest Insider Trading transactions for EDIT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-08
Eaton Bruce
SOLD
-3,184.78
11.02
-289
EVP, CHIEF BUSINESS OFFICER
2022-09-06
ROBERTSON MICHELLE
SOLD
-2,881.92
15.01
-192
EVP, CHIEF FINANCIAL OFFICER
2022-09-06
Eaton Bruce
SOLD
-1,516.01
15.01
-101
EVP, CHIEF BUSINESS OFFICER
2022-08-09
Eaton Bruce
SOLD
-5,449.39
18.5986
-293
EVP, CHIEF BUSINESS OFFICER
2022-07-18
Mei Baisong
ACQUIRED
-
-
58,372
SVP, CHIEF MEDICAL OFFICER
2022-06-15
Shearman Mark S
SOLD
-51,744.8
10.0573
-5,145
EVP, CHIEF SCIENTIFIC OFFICER
2022-06-03
ROBERTSON MICHELLE
SOLD
-17,616.8
11.5369
-1,527
EVP, CHIEF FINANCIAL OFFICER
2022-06-03
Eaton Bruce
SOLD
-12,955.9
11.5369
-1,123
EVP, CHIEF BUSINESS OFFICER
2022-06-02
O'Neill Gilmore Neil
ACQUIRED
-
-
86,655
CEO
2022-05-09
Eaton Bruce
SOLD
-3,894.5
13.1128
-297
EVP, CHIEF BUSINESS OFFICER

1–10 of 50

James C. Mullen
260
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Operations    
Collaboration and other research and development revenues$ 42$ 6,197$ 13,176$ 13,075
Revenue typeus-gaap:ServiceMemberus-gaap:ServiceMemberus-gaap:ServiceMemberus-gaap:ServiceMember
Operating expenses:    
Research and development$ 41,326$ 29,265$ 122,960$ 104,954
General and administrative16,23616,18552,72059,657
Total operating expenses57,56245,450175,680164,611
Operating loss(57,520)(39,253)(162,504)(151,536)
Other income, net:    
Other income, net119438
Interest income, net1,7931522,806432
Total other income, net1,7941712,810470
Net loss$ (55,726)$ (39,082)$ (159,694)$ (151,066)
Net loss per share, basic (in dollars per share)$ (0.81)$ (0.57)$ (2.33)$ (2.24)
Net loss per share, diluted (in dollars per share)$ (0.81)$ (0.57)$ (2.33)$ (2.24)
Weighted-average common shares outstanding, basic (in shares)68,736,12568,219,74268,621,57467,371,246
Weighted-average common shares outstanding, diluted (in shares)68,736,12568,219,74268,621,57467,371,246

EDIT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 210,704$ 203,519
Marketable securities208,913296,326
Accounts receivable120267
Prepaid expenses and other current assets6,8927,198
Total current assets426,629507,310
Marketable securities58,844120,071
Property and equipment, net15,49417,118
Right-of-use assets22,53226,173
Restricted cash and other non-current assets7,5306,811
Total assets531,029677,483
Current liabilities:  
Accounts payable6,8365,050
Accrued expenses19,25920,192
Deferred revenue, current4,22111,333
Operating lease liabilities11,97310,309
Total current liabilities42,28946,884
Operating lease liabilities, net of current portion9,32816,069
Deferred revenue, net of current portion64,66760,888
Total liabilities116,284123,841
Stockholders' equity  
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,761,729 and 68,489,257 shares issued, and 68,761,729 and 68,435,257 shares outstanding at September 30, 2022 and December 31, 2021, respectively77
Additional paid-in capital1,436,4221,411,827
Accumulated other comprehensive loss(4,291)(493)
Accumulated deficit(1,017,393)(857,699)
Total stockholders' equity414,745553,642
Total liabilities and stockholders' equity$ 531,029$ 677,483